Rhythm Pharmaceuticals Presents New Data at ESPE 2023

<p>BOSTON, Sept. 22, 2023 (GLOBE NEWSWIRE) &#8212; Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases, today announced four oral presentations at the 61st Annual European Society for Paediatric Endocrinology (ESPE) [&#8230;]</p>
<p>The post <a rel="nofollow" href="https://forextv.com/top-news/rhythm-pharmaceuticals-presents-new-data-at-espe-2023/">Rhythm Pharmaceuticals Presents New Data at ESPE 2023</a> appeared first on <a rel="nofollow" href="https://forextv.com">ForexTV</a>.</p>